Volume | 2,203,687 |
|
|||||
News | - | ||||||
Day High | 10.06 | Low High |
|||||
Day Low | 9.69 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Amicus Therapeutics Inc | FOLD | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
9.69 | 9.69 | 10.06 | 9.91 | 9.75 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
16,895 | 2,203,687 | $ 9.89 | $ 21,796,866 | - | 9.02 - 14.57 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:31:07 | formt | 100 | $ 9.89 | USD |
Amicus Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
2.92B | 295.38M | - | 399.36M | -151.58M | -0.51 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Amicus Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical FOLD Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 9.49 | 10.06 | 9.125 | 9.54 | 2,505,429 | 0.40 | 4.21% |
1 Month | 10.82 | 10.93 | 9.02 | 9.94 | 2,836,581 | -0.93 | -8.60% |
3 Months | 13.92 | 14.02 | 9.02 | 11.23 | 3,022,833 | -4.03 | -28.95% |
6 Months | 10.92 | 14.57 | 9.02 | 12.05 | 3,053,476 | -1.03 | -9.43% |
1 Year | 11.90 | 14.57 | 9.02 | 12.11 | 2,746,988 | -2.01 | -16.89% |
3 Years | 9.31 | 14.57 | 5.91 | 10.93 | 2,714,516 | 0.58 | 6.23% |
5 Years | 11.92 | 25.39 | 5.91 | 11.57 | 2,736,587 | -2.03 | -17.03% |
Amicus Therapeutics Description
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. |